Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMFCIH)

• Drug Name: Clotrimazole Drug Info
• Synonyms: Canesten; Canestene; Canestine; Canifug; Chlotrimazole; Cimitidine; Clomatin; Clotrimaderm; Clotrimazol; Clotrimazolum; Clotrimeizol; Cutistad; Empecid; Esparol; FemCare; Gynix; Kanesten; Klotrimazole; Lotrimax; Lotrimin; Monobaycuten; Mycelax; Mycelex; Mycofug; Mycosporin; Mykosporin; Nalbix; Pedisafe; Rimazole; Stiemazol; Tibatin; Trimysten; Canesten Cream; Canesten Solution; Clotrimazole Schering Brand; Desamix F; Fem Care; Gyne lotrimin; Lotrimin AF Cream; Lotrimin AF Lotion; Lotrimin AF Solution; Lotrimin Af; Lotrimin Cream; Lotrimin Lotion; Lotrimin Solution; Mycelex Cream; Mycelex G; Mycelex OTC; Mycelex Solution; Mycelex Troches; Mycelex Twin Pack; Myclo Cream; Myclo Solution; Myclo Spray Solution; Schering Brand of Clotrimazole; B 5097; Bay b 9057; Bayer Brand 1 of Clotrimazole; Bayer Brand 2 of Clotrimazole; C 6019; FB 5097; FB b 5097; Mycelex 7; Trivagizole 3; Bay-B 5097; Candid Vaginal (TN); Candinil (TN); Canesten (TN); Canesten 1-Day Therapy; Canesten 3-Day Therapy; Canesten 6-Day Therapy; Clobrate VT (TN); Clotrimazol [INN-Spanish]; Clotrimazolum [INN-Latin]; DRG-0072; Gino-Lotremine; Gyne-Lotrimin; Gyne-Lotrimin 3; Gyne-Lotrimin 3 Combination Pack; Gyne-Lotrimin Combination Pack; Lotrimin (TN); Lotrimin AF Jock-Itch Cream; Mono-baycuten; Mycelex (TN); Mycelex-7; Mycelex-7 Combination Pack; Mycelex-G; Mycelex: MycosporinRimazole; Myclo-Gyne; Neo-Zol Cream; Pan-Fungex; Cancap-VT (TN); Candid - V Gel (TN); Canesten 1-Day Cream Combi-Pak; Canesten Combi-Pak 1-Day Therapy; Canesten Combi-Pak 3-Day Therapy; Clotrimazole (JP15/USP/INN); Clotrimazole [USAN:INN:BAN:JAN]; (Chlorotrityl)imidazole; 1-(o-Chlorotrityl)imidazole

Indication

Disease Entry	ICD 11	Status	REF
Cutaneous candidiasis	1F23.14	Approved	[1]
Fungal infection	1F29-1F2F	Approved	[2]
Mycoses	1F2Z	Approved	[1]
Oral candidiasis	1F23.0	Approved	[1]
Tinea corporis	1F28.Y	Approved	[1]
Tinea cruris	1F28.3	Approved	[1]
Tinea versicolor	1F2D.0	Approved	[1]
Tinea pedis	1F28.2	Investigative	[1]

• Therapeutic Class: Antifungal Agents
• Cross-matching ID:
  PubChem CID: 2812
  ChEBI ID: CHEBI:3764
  CAS Number: CAS 23593-75-1
  TTD Drug ID: DMMFCIH
  VARIDT Drug ID: DR00574
  INTEDE Drug ID: DR0362
  ACDINA Drug ID: D00959

Molecule-Related Drug Atlas

Drug(s) Targeting C-X-C chemokine receptor type 2 (CXCR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[14]
Reparixin	DMVBA7I	Pancreatic islet transplantation failure	NE84	Phase 3	[14]
SCH-527123	DMPUAOE	Chronic obstructive pulmonary disease	CA22	Phase 2	[15]
SB-265610	DM8TKG5	Asthma	CA23	Phase 2	[16]
AZD-5069	DM3JSFK	Asthma	CA23	Phase 2	[17]
PS-938285	DMHZIFJ	Chronic obstructive pulmonary disease	CA22	Phase 2	[18]
GSK1325756	DMA6RBF	Chronic obstructive pulmonary disease	CA22	Phase 2	[19]
SB-656933	DMCY785	Chronic obstructive pulmonary disease	CA22	Phase 2	[20]
RIST4721	DMA3DKO	Hidradenitis suppurativa	ED92.0	Phase 2	[21]
SX-682	DMHMG6X	Melanoma	2C30	Phase 1	[22]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[23]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[24]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[25]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[26]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[27]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[28]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[29]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[30]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[24]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[31]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[32]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[33]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[34]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[35]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[36]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[37]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[38]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[39]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[40]

Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[41]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[42]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[43]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[44]
Cepharanthine	DM9Y5JB	N. A.	N. A.	Approved	[45]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[46]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[47]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[48]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[49]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[47]

Drug(s) Affected By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[32]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[33]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[38]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[38]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[50]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[51]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[52]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[53]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[55]

Drug(s) Affected By ATP-binding cassette sub-family C member 2 (ABCC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lopinavir	DMITQS0	Human immunodeficiency virus infection	1C62	Approved	[56]
Sulfinpyrazone	DMEV954	Gout	FA25	Approved	[57]
Probenecid	DMMFWOJ	Acute gonococcal cervicitis		Approved	[58]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[59]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[60]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[61]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[62]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[63]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[64]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[65]

Drug(s) Affected By Cytochrome P450 3A7 (CYP3A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[66]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[53]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[51]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[67]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[68]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[69]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[70]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[71]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[72]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[73]

Drug(s) Affected By Cytochrome P450 2B6 (CYP2B6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[74]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[75]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[76]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[77]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[78]
Clopidogrel	DMOL54H	Acute coronary syndrome	BA41	Approved	[79]
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[80]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[81]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[82]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[83]

Drug(s) Affected By Aromatase (CYP19A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[84]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[85]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[86]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[87]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[86]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[88]
FADROZOLE	DM3C5GZ	Breast cancer	2C60-2C65	Approved	[89]
Bifonazole	DM3KN7V	Fungal infection	1F29-1F2F	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[90]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[86]

Drug(s) Affected By Cytochrome P450 2C8 (CYP2C8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[91]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[92]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[91]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[92]
Sulfinpyrazone	DMEV954	Gout	FA25	Approved	[93]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[91]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[91]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[91]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[94]
Dabrafenib	DMX6OE3	Melanoma	2C30	Approved	[95]

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 2 (NR1I2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[96]
Vidarabine	DM0N85H	Hepatosplenic T-cell lymphoma		Approved	[96]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[97]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[98]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[99]
Etidronic acid	DM1XHYJ	Bone Paget disease		Approved	[96]
Tiaprofenic acid	DM23D7J	Osteoarthritis	FA00-FA05	Approved	[96]
Bromperidol	DM24XYQ	Schizophrenia	6A20	Approved	[96]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[100]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[101]

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 3 (NR1I3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[100]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[102]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[103]
Artemether	DM48QOT	Malaria	1F40-1F45	Approved	[104]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[105]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[106]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[107]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[108]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[109]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[53]

Drug(s) Affected By Bile salt export pump (ABCB11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[110]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[12]
Glipizide	DMZA5PQ	Diabetic complication	5A2Y	Approved	[12]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[111]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[110]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[12]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[112]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[110]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[113]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[110]

Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[33]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[114]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[36]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[35]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[115]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[116]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[36]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[117]
Fluconazole	DMOWZ6B	Cryptococcal meningitis		Approved	[35]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[36]

Drug(s) Affected By ATP-binding cassette sub-family C member 3 (ABCC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[64]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[118]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[119]
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[120]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[121]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[122]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[123]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[124]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[125]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[126]

Drug(s) Affected By Intermediate conductance calcium-activated potassium channel protein 4 (KCNN4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[127]
Chlorzoxazone	DMCYVDT	Acute pain	MG31	Approved	[128]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[129]
Charybdotoxin	DMKN345	Scorpion envenoming syndrome	8D43	Approved	[130]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[131]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[123]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[132]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[133]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[134]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[135]

Drug(s) Affected By Adenylate cyclase type 9 (ADCY9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[136]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[137]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[53]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[138]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[139]
Miconazole	DMPMYE8	Cutaneous candidiasis	1F23.14	Approved	[5]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[140]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[65]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[141]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[142]

Drug(s) Affected By Protein c-Fos (FOS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[143]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[144]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[145]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[146]
Acebutolol	DM0TI4U	Hypertension	BA00-BA04	Approved	[145]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[122]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[147]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[148]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[149]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[150]

Drug(s) Affected By Myc proto-oncogene protein (MYC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[151]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[146]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[122]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[152]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[136]
Selenium	DM25CGV	N. A.	N. A.	Approved	[153]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[154]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[155]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[156]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[88]

Drug(s) Affected By Cellular tumor antigen p53 (TP53)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[157]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[88]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[158]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[159]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[160]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[161]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[162]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[163]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[164]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[165]

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[166]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[167]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[168]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[169]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[170]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[171]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[172]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[173]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[174]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[175]

Drug(s) Affected By Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[176]
FADROZOLE	DM3C5GZ	Breast cancer	2C60-2C65	Approved	[89]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[177]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[178]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[179]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[179]
Pyruvic acid	DM7Q41G	Malnutrition	5B50-5B71	Approved	[180]
Topiramate	DM82Z30	Alcohol dependence	6C40.2	Approved	[181]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[181]
ABIRATERONE	DM8V75C	Prostate cancer	2C82.0	Approved	[182]

Drug(s) Affected By Cyclin-dependent kinase 1 (CDK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[183]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[184]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[185]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[123]
Selenium	DM25CGV	N. A.	N. A.	Approved	[153]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[186]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[187]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[188]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[189]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[190]

Drug(s) Affected By ATP-dependent 6-phosphofructokinase, muscle type (PFKM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[10]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[191]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[192]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[132]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[193]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[194]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[195]
Bardoxolone methyl	DMODA2X	Mixed connective tissue disease	4A43.3	Phase 3	[196]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[197]

Drug(s) Affected By Insulin-like growth factor-binding protein 1 (IGFBP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[87]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[198]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[199]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[200]
Lisinopril	DMUOK4C	Chronic heart failure	BD1Z	Approved	[201]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[202]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[203]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[203]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[137]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[53]

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[204]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[205]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[206]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[207]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[208]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[209]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[210]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[211]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[212]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[210]

Drug(s) Affected By Cyclin-dependent kinase 4 (CDK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[213]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[214]
Selenium	DM25CGV	N. A.	N. A.	Approved	[153]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[215]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[188]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[216]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[217]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[190]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[218]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[219]

Drug(s) Affected By Glial fibrillary acidic protein (GFAP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Penicillin V	DMKVOYF	Acute otitis media	AB00	Approved	[220]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[220]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[221]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[222]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[223]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[224]
Haloperidol	DM96SE0	Delirium		Approved	[225]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[191]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[226]

Drug(s) Affected By Cyclic AMP-dependent transcription factor ATF-3 (ATF3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[227]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[228]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[229]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[230]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[189]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[231]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[199]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[200]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[219]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[232]

Drug(s) Affected By Aryl hydrocarbon receptor (AHR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[87]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[233]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[234]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[235]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[236]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[237]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[238]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[239]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[107]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[240]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[241]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[144]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[242]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[243]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[244]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[228]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[186]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[245]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[246]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[247]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1B (CDKN1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[248]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[249]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[245]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[250]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[251]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[252]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[253]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[254]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[255]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[256]

Drug(s) Affected By Hexokinase-2 (HK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[123]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[257]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[199]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[239]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[258]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[10]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[137]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[259]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[260]

Drug(s) Affected By Heat shock factor protein 1 (HSF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[261]
SPI-1005	DM6XFHS	Reperfusion injury	ND56.Z	Approved	[262]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[262]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[263]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[264]
Ceftazidime	DM41GRA	Bacteremia	1A73	Approved	[262]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[219]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[262]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[262]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[262]

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[265]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[266]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[267]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[268]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[268]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[269]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[270]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[271]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[272]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[268]

Drug(s) Affected By Cytochrome P450 1B1 (CYP1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[167]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[228]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[273]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[274]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[275]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[276]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[277]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[278]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[279]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[207]

Drug(s) Affected By Eukaryotic translation initiation factor 2A (EIF2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[280]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[281]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[282]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[283]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[284]
Cerulenin	DM6N4PR	Weight loss	MG43.5	Approved	[285]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[286]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[287]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[53]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[54]

Drug(s) Affected By DnaJ homolog subfamily B member 4 (DNAJB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[227]
Selenium	DM25CGV	N. A.	N. A.	Approved	[288]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[199]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[171]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[289]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[232]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[136]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[290]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[291]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[227]

Drug(s) Affected By Lanosterol 14-alpha demethylase (CYP51A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[292]
FADROZOLE	DM3C5GZ	Breast cancer	2C60-2C65	Approved	[293]
Bifonazole	DM3KN7V	Fungal infection	1F29-1F2F	Approved	[293]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[199]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[73]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[219]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[294]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[286]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[224]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[137]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-X-C chemokine receptor type 2 (CXCR2)	TT30C9G	CXCR2_HUMAN	Modulator	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Adenylate cyclase type 9 (ADCY9)	OT1IZT5K	ADCY9_HUMAN	Gene/Protein Processing	[5]
Aromatase (CYP19A1)	OTZ6XF74	CP19A_HUMAN	Gene/Protein Processing	[6]
Aryl hydrocarbon receptor (AHR)	OTFE4EYE	AHR_HUMAN	Gene/Protein Processing	[7]
ATP-binding cassette sub-family C member 2 (ABCC2)	OTJSIGV5	MRP2_HUMAN	Gene/Protein Processing	[8]
ATP-binding cassette sub-family C member 3 (ABCC3)	OTC3IJV4	MRP3_HUMAN	Gene/Protein Processing	[9]
ATP-dependent 6-phosphofructokinase, muscle type (PFKM)	OT1QY9JM	PFKAM_HUMAN	Gene/Protein Processing	[10]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[11]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[12]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Gene/Protein Processing	[13]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3)	OTC1UOHP	ATF3_HUMAN	Gene/Protein Processing	[9]

References

• [1] Clotrimazole FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2330).
• [3] Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44.
• [4] Tacrolimus interaction with clotrimazole: a concise case report and literature review. P T. 2010 Oct;35(10):568-9.
• [5] Direct stimulation of adenylyl cyclase 9 by the fungicide imidazole miconazole. Naunyn Schmiedebergs Arch Pharmacol. 2019 Apr;392(4):497-504. doi: 10.1007/s00210-018-01610-1. Epub 2019 Jan 3.
• [6] Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans. Endocr Res. 2004 Aug;30(3):387-94.
• [7] Improved assays for xenosensor activation based on reverse transfection. Toxicol In Vitro. 2015 Oct;29(7):1759-65. doi: 10.1016/j.tiv.2015.07.011. Epub 2015 Jul 14.
• [8] Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology. 2002 Feb 28;171(2-3):137-46.
• [9] Activation of p38 Mitogen-Activated Protein Kinase by Clotrimazole Induces Multidrug Resistance-Associated Protein 3 Activation through a Novel Transcriptional Element. J Pharmacol Exp Ther. 2016 Oct;359(1):102-9. doi: 10.1124/jpet.115.231589. Epub 2016 Aug 9.
• [10] Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells. Chem Biol Interact. 2015 May 25;233:147-56. doi: 10.1016/j.cbi.2015.03.028. Epub 2015 Apr 8.
• [11] Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8.
• [12] Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
• [13] Effects of clotrimazole on the growth, morphological characteristics, and cisplatin sensitivity of human glioblastoma cells in vitro. J Neurosurg. 1999 May;90(5):918-27. doi: 10.3171/jns.1999.90.5.0918.
• [14] 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
• [15] CXCR2 Antagonist MK-7123.A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med.2015 May 1;191(9):1001-11.
• [16] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [17] Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50.
• [18] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [19] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [20] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [21] A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. Dermatol Ther (Heidelb). 2021 Dec;11(6):2179-2193.
• [22] Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431.
• [23] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [24] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [25] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [26] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [27] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [28] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [29] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [30] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [31] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [32] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
• [33] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [34] Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
• [35] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [36] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [37] Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
• [38] Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
• [39] Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
• [40] Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
• [41] Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
• [42] Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
• [43] Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
• [44] Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
• [45] Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
• [46] Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
• [47] Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
• [48] Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
• [49] Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
• [50] Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab Dispos. 2005 Jul;33(7):1074-81. doi: 10.1124/dmd.104.002279. Epub 2005 Apr 8.
• [51] Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
• [52] Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity. J Toxicol Sci. 2017;42(3):343-348.
• [53] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [54] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [55] Induction of hepatic CYP3A enzymes by pregnancy-related hormones: studies in human hepatocytes and hepatic cell lines. Drug Metab Dispos. 2013 Feb;41(2):281-90.
• [56] Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition. Pharmacogenet Genomics. 2011 Dec;21(12):884-93. doi: 10.1097/FPC.0b013e32834d672b.
• [57] Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity. J Pharmacol Exp Ther. 2004 Jan;308(1):260-7. doi: 10.1124/jpet.103.057729. Epub 2003 Oct 20.
• [58] MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9. doi: 10.1002/ijc.21013.
• [59] Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 2008 May;99(5):967-72.
• [60] Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 2013 Nov;65(11):2791-802.
• [61] In vitro study of transporters involved in intestinal absorption of inorganic arsenic. Chem Res Toxicol. 2012 Feb 20;25(2):446-53. doi: 10.1021/tx200491f. Epub 2012 Jan 26.
• [62] Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46. doi: 10.1093/toxsci/kfu151. Epub 2014 Jul 23.
• [63] Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells. Chem Biol Interact. 2015 Dec 5;242:13-23. doi: 10.1016/j.cbi.2015.08.023. Epub 2015 Sep 1.
• [64] Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck. 2011 Jul;33(7):959-68. doi: 10.1002/hed.21559. Epub 2010 Aug 24.
• [65] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [66] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [67] Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
• [68] Human drug metabolism genes in parathion-and estrogen-treated breast cells. Int J Mol Med. 2007 Dec;20(6):875-81.
• [69] Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol. 2009 Feb 1;234(3):345-60.
• [70] Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther. 2006 Nov;80(5):440-456.
• [71] Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther. 2005 Aug;314(2):626-35. doi: 10.1124/jpet.105.086504. Epub 2005 Apr 21.
• [72] Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol. 2010 Nov;161(5):1059-69. doi: 10.1111/j.1476-5381.2010.00946.x.
• [73] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [74] Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
• [75] Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
• [76] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [77] Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor. Chem Res Toxicol. 2014 Feb 17;27(2):304-308.
• [78] Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem. 2004 Jul 9;279(28):29295-301. doi: 10.1074/jbc.M400580200. Epub 2004 Apr 28.
• [79] Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3. Arch Toxicol. 2019 Aug;93(8):2247-2264. doi: 10.1007/s00204-019-02495-6. Epub 2019 Jul 16.
• [80] Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
• [81] Characterization of human cytochrome P450 induction by pesticides. Toxicology. 2012 Mar 29;294(1):17-26.
• [82] Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys. 2005 Feb 1;434(1):75-85.
• [83] Pyrethroids: cytotoxicity and induction of CYP isoforms in human hepatocytes. Drug Metabol Drug Interact. 2008;23(3-4):211-36.
• [84] Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res. 2005 Apr 15;11(8):2809-21. doi: 10.1158/1078-0432.CCR-04-2187.
• [85] Cannabidiol (CBD) but not tetrahydrocannabinol (THC) dysregulate in vitro decidualization of human endometrial stromal cells by disruption of estrogen signaling. Reprod Toxicol. 2020 Apr;93:75-82. doi: 10.1016/j.reprotox.2020.01.003. Epub 2020 Jan 14.
• [86] Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay. Toxicol In Vitro. 2015 Oct;29(7):1729-35.
• [87] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [88] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [89] Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 10;48(5):1563-75.
• [90] Estrogen synthesis in human colon cancer epithelial cells. J Steroid Biochem Mol Biol. 1999 Dec 31;71(5-6):223-30.
• [91] Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
• [92] Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
• [93] Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys. 2003 Jan 1;409(1):32-44.
• [94] Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chem Biol Interact. 2021 Apr 1;338:109401. doi: 10.1016/j.cbi.2021.109401. Epub 2021 Feb 5.
• [95] Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicol Appl Pharmacol. 2022 Jan 1;434:115797. doi: 10.1016/j.taap.2021.115797. Epub 2021 Nov 13.
• [96] Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
• [97] Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta. 2005 May 30;1740(2):162-9. doi: 10.1016/j.bbadis.2004.11.013. Epub 2004 Dec 8.
• [98] Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33. doi: 10.1016/j.taap.2005.03.015.
• [99] Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
• [100] Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
• [101] Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.
• [102] Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res. 2009 Apr;26(4):872-82.
• [103] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [104] Fetal bovine serum and human constitutive androstane receptor: evidence for activation of the SV23 splice variant by artemisinin, artemether, and arteether in a serum-free cell culture system. Toxicol Appl Pharmacol. 2014 Jun 1;277(2):221-30. doi: 10.1016/j.taap.2014.03.023. Epub 2014 Apr 12.
• [105] Constitutive androstane/active receptor is a target of retinoic acid receptor in humans. Biochem Pharmacol. 2010 Jul 1;80(1):129-35. doi: 10.1016/j.bcp.2010.02.023. Epub 2010 Mar 6.
• [106] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [107] Expression and inducibility of cytochrome P450s (CYP1A1, 2B6, 2E1, 3A4) in human cord blood CD34(+) stem cell-derived differentiating neuronal cells. Toxicol Sci. 2012 Oct;129(2):392-410.
• [108] Agonistic effects of diverse xenobiotics on the constitutive androstane receptor as detected in a recombinant yeast-cell assay. Toxicol In Vitro. 2018 Feb;46:335-349. doi: 10.1016/j.tiv.2017.09.014. Epub 2017 Sep 18.
• [109] Teriflunomide is an indirect human constitutive androstane receptor (CAR) activator interacting with epidermal growth factor (EGF) signaling. Front Pharmacol. 2018 Oct 11;9:993.
• [110] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [111] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [112] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [113] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [114] Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
• [115] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [116] Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
• [117] The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
• [118] Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis. Biochem Pharmacol. 2009 Apr 15;77(8):1410-7.
• [119] Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol. 2005 May 14;11(18):2748-53. doi: 10.3748/wjg.v11.i18.2748.
• [120] Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
• [121] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [122] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [123] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [124] Differential regulation of the human MRP2 and MRP3 gene expression by glucocorticoids. J Steroid Biochem Mol Biol. 2005 Aug;96(3-4):229-34. doi: 10.1016/j.jsbmb.2005.03.004.
• [125] Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun. 2002 Feb 8;290(5):1427-33. doi: 10.1006/bbrc.2002.6367.
• [126] Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol. 2008 Aug;74(2):476-84.
• [127] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [128] Functional and molecular identification of intermediate-conductance Ca(2+)-activated K(+) channels in breast cancer cells: association with cell cycle progression. Am J Physiol Cell Physiol. 2004 Jul;287(1):C125-34. doi: 10.1152/ajpcell.00488.2003. Epub 2004 Feb 25.
• [129] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [130] 4-Chlorobenzo[F]isoquinoline (CBIQ), a novel activator of CFTR and DeltaF508 CFTR. Eur J Pharmacol. 2005 Jun 1;516(2):118-24. doi: 10.1016/j.ejphar.2005.04.037.
• [131] Decitabine up-regulates S100A2 expression and synergizes with IFN-gamma to kill uveal melanoma cells. Clin Cancer Res. 2007 Sep 1;13(17):5219-25. doi: 10.1158/1078-0432.CCR-07-0816.
• [132] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [133] Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol Biol Cell. 2004 Mar;15(3):1262-72. doi: 10.1091/mbc.e03-06-0360. Epub 2003 Dec 29.
• [134] A novel long noncoding RNA AK001796 acts as an oncogene and is involved in cell growth inhibition by resveratrol in lung cancer. Toxicol Appl Pharmacol. 2015 Jun 1;285(2):79-88.
• [135] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [136] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [137] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [138] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [139] Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
• [140] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [141] Expression profiling of nucleotide metabolism-related genes in human breast cancer cells after treatment with 5-fluorouracil. Cancer Invest. 2009 Jun;27(5):561-7.
• [142] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [143] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [144] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [145] Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro. Toxicol Sci. 2003 Aug;74(2):260-70. doi: 10.1093/toxsci/kfg113. Epub 2003 May 2.
• [146] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [147] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [148] Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis Res Ther. 2014 Jan 20;16(1):R17. doi: 10.1186/ar4444.
• [149] Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation. Cardiovasc Res. 2005 Aug 1;67(2):333-41. doi: 10.1016/j.cardiores.2005.03.016. Epub 2005 Apr 21.
• [150] The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004 Jun 25;279(26):27008-16. doi: 10.1074/jbc.M403588200. Epub 2004 Apr 16.
• [151] Acetaminophen-induced proliferation of estrogen-responsive breast cancer cells is associated with increases in c-myc RNA expression and NF-kappaB activity. Toxicol Sci. 2002 Apr;66(2):233-43. doi: 10.1093/toxsci/66.2.233.
• [152] ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Mol Cancer Ther. 2007 May;6(5):1579-87. doi: 10.1158/1535-7163.MCT-06-0814.
• [153] Selenite and selenomethionine promote HL-60 cell cycle progression. J Nutr. 2002 Apr;132(4):674-9. doi: 10.1093/jn/132.4.674.
• [154] Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
• [155] Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
• [156] Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. Cancer Res. 2002 Nov 1;62(21):6006-10.
• [157] p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer. 2005 Apr 10;114(3):331-6. doi: 10.1002/ijc.20818.
• [158] Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
• [159] Quantitative analysis of gene expression changes in response to genotoxic compounds. Toxicol In Vitro. 2017 Mar;39:15-28. doi: 10.1016/j.tiv.2016.11.004. Epub 2016 Nov 5.
• [160] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [161] Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
• [162] Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Res. 2009 Jan;37(1):78-95. doi: 10.1093/nar/gkn910. Epub 2008 Nov 16.
• [163] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [164] Nitrogen Mustard Alkylates and Cross-Links p53 in Human Keratinocytes. Chem Res Toxicol. 2022 Apr 18;35(4):636-650. doi: 10.1021/acs.chemrestox.1c00420. Epub 2022 Mar 21.
• [165] Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer. 2013 Nov 12;109(10):2751-62. doi: 10.1038/bjc.2013.583. Epub 2013 Oct 29.
• [166] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [167] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [168] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [169] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [170] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [171] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [172] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [173] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [174] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [175] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
• [176] Retinoids and retinol differentially regulate steroid biosynthesis in ovarian theca cells isolated from normal cycling women and women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 Aug;90(8):4858-65. doi: 10.1210/jc.2005-0330. Epub 2005 May 24.
• [177] Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity. J Mol Endocrinol. 2004 Apr;32(2):425-36.
• [178] Use of organ culture to study the human fetal testis development: effect of retinoic acid. J Clin Endocrinol Metab. 2006 Jul;91(7):2696-703.
• [179] Inhibition of CYP17 expression by adrenal androgens and transforming growth factor beta in adrenocortical cells. Acta Biochim Pol. 2004;51(4):907-17.
• [180] Phosphorylation of CtBP1 by cAMP-dependent protein kinase modulates induction of CYP17 by stimulating partnering of CtBP1 and 2. J Biol Chem. 2008 Mar 14;283(11):6925-34. doi: 10.1074/jbc.M708432200. Epub 2008 Jan 9.
• [181] Effects of anticonvulsants on human p450c17 (17alpha-hydroxylase/17,20 lyase) and 3beta-hydroxysteroid dehydrogenase type 2. Epilepsia. 2005 Mar;46(3):444-8.
• [182] A fission yeast-based test system for the determination of IC50 values of anti-prostate tumor drugs acting on CYP21. J Enzyme Inhib Med Chem. 2006 Oct;21(5):547-56.
• [183] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [184] G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem. 1993 Apr 15;268(11):8298-308.
• [185] mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
• [186] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [187] Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
• [188] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [189] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [190] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [191] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [192] Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther. 2012 Aug;11(8):1703-12.
• [193] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [194] Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
• [195] Resveratrol decreases breast cancer cell viability and glucose metabolism by inhibiting 6-phosphofructo-1-kinase. Biochimie. 2013 Jun;95(6):1336-43. doi: 10.1016/j.biochi.2013.02.013. Epub 2013 Feb 27.
• [196] Synthetic oleanane triterpenoid derivative CDDO-Me disrupts cellular bioenergetics to suppress pancreatic ductal adenocarcinoma via targeting SLC1A5. J Biochem Mol Toxicol. 2022 Nov;36(11):e23192. doi: 10.1002/jbt.23192. Epub 2022 Aug 5.
• [197] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [198] Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis. Toxicol Appl Pharmacol. 2016 Jul 1;302:1-9. doi: 10.1016/j.taap.2016.04.007. Epub 2016 Apr 16.
• [199] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [200] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [201] Tissue availability of insulin-like growth factor I is inversely related to insulin resistance in essential hypertension: effects of angiotensin converting enzyme inhibition. J Hypertens. 1998 Jun;16(6):863-70. doi: 10.1097/00004872-199816060-00018.
• [202] Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
• [203] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [204] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [205] Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
• [206] Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
• [207] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [208] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [209] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [210] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [211] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [212] Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
• [213] p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol. 2012 Jul;14(7):870-81. doi: 10.1093/neuonc/nos114. Epub 2012 Jun 18.
• [214] In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells. Food Chem Toxicol. 2022 Jan;159:112722. doi: 10.1016/j.fct.2021.112722. Epub 2021 Dec 3.
• [215] JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo. Eur J Pharmacol. 2007 Apr 10;560(2-3):95-100. doi: 10.1016/j.ejphar.2007.01.020. Epub 2007 Jan 19.
• [216] Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 2010 Nov;26(5):735-41. doi: 10.3892/ijmm_00000520.
• [217] A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol. 2011 Jan;120(1):121-7. doi: 10.1016/j.ygyno.2010.10.003. Epub 2010 Oct 29.
• [218] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [219] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [220] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [221] miRNA expression profiling in a human stem cell-based model as a tool for developmental neurotoxicity testing. Cell Biol Toxicol. 2013 Aug;29(4):239-57. doi: 10.1007/s10565-013-9250-5. Epub 2013 Aug 1.
• [222] A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. Tohoku J Exp Med. 2008 May;215(1):55-9. doi: 10.1620/tjem.215.55.
• [223] Aspirin-induced blockade of NF-kappaB activity restrains up-regulation of glial fibrillary acidic protein in human astroglial cells. Biochim Biophys Acta. 2006 Mar;1763(3):282-9. doi: 10.1016/j.bbamcr.2006.01.005. Epub 2006 Feb 21.
• [224] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [225] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [226] Effects of acute ethanol treatment on NCCIT cells and NCCIT cell-derived embryoid bodies (EBs). Toxicol In Vitro. 2010 Sep;24(6):1696-704. doi: 10.1016/j.tiv.2010.05.017. Epub 2010 May 26.
• [227] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [228] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [229] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [230] Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
• [231] Identification of novel activators of the metal responsive transcription factor (MTF-1) using a gene expression biomarker in a microarray compendium. Metallomics. 2020 Sep 23;12(9):1400-1415. doi: 10.1039/d0mt00071j.
• [232] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [233] Oxidative stress modulates expression of immune checkpoint genes via activation of AhR signaling. Toxicol Appl Pharmacol. 2022 Dec 15;457:116314. doi: 10.1016/j.taap.2022.116314. Epub 2022 Nov 9.
• [234] Profiling of enantiopure drugs towards aryl hydrocarbon (AhR), glucocorticoid (GR) and pregnane X (PXR) receptors in human reporter cell lines. Chem Biol Interact. 2014 Feb 5;208:64-76. doi: 10.1016/j.cbi.2013.11.018. Epub 2013 Dec 6.
• [235] Involvement of cytoskeleton in AhR-dependent CYP1A1 expression. Curr Drug Metab. 2006 Apr;7(3):301-13. doi: 10.2174/138920006776359310.
• [236] Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer. 2008 Mar 1;122(5):990-8.
• [237] Quercetin, quercetin glycosides and taxifolin differ in their ability to induce AhR activation and CYP1A1 expression in HepG2 cells. Phytother Res. 2012 Nov;26(11):1746-52.
• [238] Omeprazole inhibits pancreatic cancer cell invasion through a nongenomic aryl hydrocarbon receptor pathway. Chem Res Toxicol. 2015 May 18;28(5):907-18.
• [239] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [240] Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008 Oct;49(10):2142-8.
• [241] Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
• [242] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [243] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [244] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [245] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [246] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [247] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [248] Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.
• [249] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [250] Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum. 2012 Jun;64(6):1780-9. doi: 10.1002/art.34342. Epub 2011 Dec 19.
• [251] Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008 Apr;18(2):85-94. doi: 10.1097/CMR.0b013e3282f60097.
• [252] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [253] Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol. 2001 May 15;61(10):1205-15. doi: 10.1016/s0006-2952(01)00583-4.
• [254] Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol. 2008 May 15;75(10):1924-34. doi: 10.1016/j.bcp.2008.02.013. Epub 2008 Feb 17.
• [255] Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Anticancer Res. 2003 Jan-Feb;23(1A):267-73.
• [256] Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol. 2007 Feb;4(1):59-63.
• [257] Epinephrine facilitates the growth of T cell lymphoma by altering cell proliferation, apoptosis, and glucose metabolism. Chem Biol Interact. 2023 Jan 5;369:110278. doi: 10.1016/j.cbi.2022.110278. Epub 2022 Nov 22.
• [258] Systematic identification of arsenic-binding proteins reveals that hexokinase-2 is inhibited by arsenic. Proc Natl Acad Sci U S A. 2015 Dec 8;112(49):15084-9. doi: 10.1073/pnas.1521316112. Epub 2015 Nov 23.
• [259] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [260] Ivermectin accelerates autophagic death of glioma cells by inhibiting glycolysis through blocking GLUT4 mediated JAK/STAT signaling pathway activation. Environ Toxicol. 2022 Apr;37(4):754-764. doi: 10.1002/tox.23440. Epub 2021 Dec 14.
• [261] NRF2 transcriptionally activates the heat shock factor 1 promoter under oxidative stress and affects survival and migration potential of MCF7 cells. J Biol Chem. 2018 Dec 14;293(50):19303-19316. doi: 10.1074/jbc.RA118.003376. Epub 2018 Oct 11.
• [262] A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
• [263] Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine. 1999 May;11(5):347-58. doi: 10.1006/cyto.1998.0437.
• [264] Simvastatin induces heat shock factor 1 in vascular endothelial cells. Atherosclerosis. 2006 Oct;188(2):265-73. doi: 10.1016/j.atherosclerosis.2005.10.045. Epub 2005 Dec 20.
• [265] Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
• [266] Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
• [267] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [268] Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
• [269] Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
• [270] Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
• [271] Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
• [272] Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.
• [273] Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
• [274] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [275] In vitro aromatic bioactivation of the weak estrogen E(2)alpha and genesis of DNA adducts. Steroids. 2005 Mar;70(3):161-72. doi: 10.1016/j.steroids.2004.11.004.
• [276] Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
• [277] Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
• [278] Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
• [279] Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
• [280] Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation. Neuro Oncol. 2011 Mar;13(3):267-79. doi: 10.1093/neuonc/noq195. Epub 2011 Feb 3.
• [281] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [282] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [283] Endoplasmic Reticulum Stress Induction and ERK1/2 Activation Contribute to Nefazodone-Induced Toxicity in Hepatic Cells. Toxicol Sci. 2016 Dec;154(2):368-380. doi: 10.1093/toxsci/kfw173. Epub 2016 Sep 9.
• [284] [Mechanism of arsenic trioxide induced apoptosis in cultured human lens epithelium cells]. Zhonghua Yan Ke Za Zhi. 2008 Oct;44(10):916-20.
• [285] Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res. 2007 Feb 1;67(3):1262-9. doi: 10.1158/0008-5472.CAN-06-1794.
• [286] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [287] Ouabain induces apoptotic cell death in human prostate DU 145 cancer cells through DNA damage and TRAIL pathways. Environ Toxicol. 2019 Dec;34(12):1329-1339. doi: 10.1002/tox.22834. Epub 2019 Aug 21.
• [288] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [289] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [290] An in vitro skin sensitization assay termed EpiSensA for broad sets of chemicals including lipophilic chemicals and pre/pro-haptens. Toxicol In Vitro. 2017 Apr;40:11-25. doi: 10.1016/j.tiv.2016.12.005. Epub 2016 Dec 10.
• [291] Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cells. Lipids Health Dis. 2010 Jun 2;9:56. doi: 10.1186/1476-511X-9-56.
• [292] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [293] Comparison of lanosterol-14 alpha-demethylase (CYP51) of human and Candida albicans for inhibition by different antifungal azoles. Toxicology. 2006 Nov 10;228(1):24-32. doi: 10.1016/j.tox.2006.08.007. Epub 2006 Aug 12.
• [294] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.